Dihydroisotanshinone I could inhibit tumor migration and cell motility, block macrophage recruitment by lung cancer cells, reduce CCL2 secretion, and suppress p-STAT3 signaling in NSCLC A549 and H460 cells [129]. This evidence concerns the gene CCL2 and neoplasm.